-
501
ЖОРСТКІСТЬ ПАРЕНХІМИ ПЕЧІНКИ ЩУРІВ ПРИ МОДЕЛЮВАННІ СТЕАТОЗУ АЛІМЕНТАРНОГО ГЕНЕЗУ ТА ЙОГО КОРЕКЦІЇ...
Published 2019-12-01Subjects: “…nonalcoholic fatty liver disease, morphological investigations, liver stiffness, shift wave elastography, steatosis, coenzyme q10, methadoxine…”
Get full text
Article -
502
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD
Published 2025-01-01Subjects: “…metabolic dysfunction-associated steatotic liver disease…”
Get full text
Article -
503
Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12)
Published 2018-08-01Get full text
Article -
504
Hu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice
Published 2025-01-01Subjects: “…metabolic dysfunction-associated steatotic liver disease…”
Get full text
Article -
505
-
506
Characteristics of different lipid droplet-mitochondrial contacts patterns during lipid droplet metabolism in T2DM-induced MASLD
Published 2025-01-01Subjects: “…Nonalcoholic fatty liver disease…”
Get full text
Article -
507
Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling
Published 2025-02-01Subjects: “…cholestatic liver diseases…”
Get full text
Article -
508
Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12)
Published 2018-08-01“…Original study included overall 180 patients with nonalcoholic fatty liver disease that were randomized to the basic and control groups in the ratio of 2:1. …”
Get full text
Article -
509
Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome—An Update
Published 2025-01-01Subjects: “…nonalcoholic fatty liver disease (NAFLD)…”
Get full text
Article -
510
Construction of a Compound Model to Enhance the Accuracy of Hepatic Fat Fraction Estimation with Quantitative Ultrasound
Published 2025-01-01Subjects: “…metabolic dysfunction-associated steatotic liver disease…”
Get full text
Article -
511
-
512
-
513
-
514
A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response
Published 2025-02-01Get full text
Article -
515
MetALD: Clinical aspects, pathophysiology and treatmentKeypoints
Published 2025-02-01“…Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) are the most prevalent causes of chronic liver disease worldwide. …”
Get full text
Article -
516
-
517
Sleeve gastrectomy reveals the plasticity of the human gastric epithelium
Published 2025-01-01Get full text
Article -
518
The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey
Published 2025-01-01Get full text
Article -
519
-
520
The Role of Iron in the Pathophysiology and Treatment of Chronic Hepatitis C
Published 2009-01-01“…The present article reviews the prevalence and risk factors for hepatic iron overload in chronic hepatitis C, with emphasis on the available data regarding the efficacy of iron depletion in the treatment of this common liver disease.…”
Get full text
Article